Cédric Rebe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1835695/publications.pdf

Version: 2024-02-01

72 7,513 papers citations

76326 40 h-index 95266 68 g-index

76 all docs 76 docs citations

76 times ranked 12537 citing authors

#	Article	IF	Citations
1	Can the hyperthermiaâ€mediated heat shock factor/heat shock protein 70 pathway dampen the cytokine storm during SARSâ€CoVâ€2 infection?. British Journal of Pharmacology, 2022, 179, 4910-4916.	5.4	6
2	MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells. Cancer Cell, 2022, 40, 136-152.e12.	16.8	79
3	Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses. Nature Immunology, 2022, 23, 262-274.	14.5	47
4	Editorial: Inflammasomes: Cornerstone of Immunity. Frontiers in Cell and Developmental Biology, 2022, 10, 888378.	3.7	0
5	Follicular helper-T cells restore CD8 ⁺ -dependent antitumor immunity and anti-PD-L1/PD-1 efficacy., 2021, 9, e002157.		63
6	Platinum Derivatives Effects on Anticancer Immune Response. Biomolecules, 2020, 10, 13.	4.0	55
7	Interplay between Liver X Receptor and Hypoxia Inducible Factor $1\hat{l}_{\pm}$ Potentiates Interleukin- $1\hat{l}_{\pm}^2$ Production in Human Macrophages. Cell Reports, 2020, 31, 107665.	6.4	39
8	Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers. Oncolmmunology, 2020, 9, 1836766.	4.6	15
9	Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency. Cancers, 2020, 12, 3550.	3.7	12
10	Heat shock and HSP70 regulate 5-FU-mediated caspase-1 activation in myeloid-derived suppressor cells and tumor growth in mice. , 2020, 8, e000478.		15
11	Interleukin- $\hat{I^2}$ and Cancer. Cancers, 2020, 12, 1791.	3.7	146
12	Cathepsin B Is Required for NLRP3 Inflammasome Activation in Macrophages, Through NLRP3 Interaction. Frontiers in Cell and Developmental Biology, 2020, 8, 167.	3.7	103
13	Monitoring HSP70 exosomes in cancer patients' follow up: a clinical prospective pilot study. Journal of Extracellular Vesicles, 2020, 9, 1766192.	12.2	71
14	Hypotonic stress enhances colon cancer cell death induced by platinum derivatives and immunologically improves antitumor efficacy of intraperitoneal chemotherapy. International Journal of Cancer, 2019, 145, 3101-3111.	5.1	3
15	P07.02 Enhanced glycolysis in glioblastomas is associated with tumor cells migration. Neuro-Oncology, 2019, 21, iii36-iii37.	1.2	0
16	STAT3, a Master Regulator of Anti-Tumor Immune Response. Cancers, 2019, 11, 1280.	3.7	68
17	Heat Shock Proteins and Inflammasomes. International Journal of Molecular Sciences, 2019, 20, 4508.	4.1	45
18	Docosahexaenoic acid inhibits both NLRP3 inflammasome assembly and JNK-mediated mature IL- $\hat{1}^2$ secretion in 5-fluorouracil-treated MDSC: implication in cancer treatment. Cell Death and Disease, 2019, 10, 485.	6.3	34

#	Article	IF	Citations
19	HSP70 is a negative regulator of NLRP3 inflammasome activation. Cell Death and Disease, 2019, 10, 256.	6.3	81
20	Anti-MEK and Anti-EGFR mAbs in RAS-Mutant Metastatic Colorectal Cancer: Case Series and Rationale. Advances in Therapy, 2019, 36, 1480-1484.	2.9	5
21	Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study. Oncolmmunology, 2018, 7, e1474319.	4.6	63
22	5-fluorouracil plus bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): An investigator-initiated, open-label, single-arm, multicentre, phase 2 study Journal of Clinical Oncology, 2018, 36, e15540-e15540.	1.6	4
23	Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation. Cell Reports, 2017, 19, 746-759.	6.4	104
24	Carob leaf polyphenols trigger intrinsic apoptotic pathway and induce cell cycle arrest in colon cancer cells. Journal of Functional Foods, 2017, 33, 112-121.	3.4	36
25	Phenolic extract from oleaster (Olea europaea var. Sylvestris) leaves reduces colon cancer growth and induces caspase-dependent apoptosis in colon cancer cells via the mitochondrial apoptotic pathway. PLoS ONE, 2017, 12, e0170823.	2.5	28
26	Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen. Cancer Research, 2016, 76, 5241-5252.	0.9	203
27	Inhibition of colon cancer growth by docosahexaenoic acid involves autocrine production of TNFα. Oncogene, 2016, 35, 4611-4622.	5.9	40
28	Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer. Journal of the National Cancer Institute, 2016, 108, djv330.	6.3	159
29	Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?. Oncotarget, 2016, 7, 9309-9321.	1.8	30
30	The receptor NLRP3 is a transcriptional regulator of TH2 differentiation. Nature Immunology, 2015, 16, 859-870.	14.5	312
31	Induction of pyroptosis in colon cancer cells by LXRβ. Molecular and Cellular Oncology, 2015, 2, e970094.	0.7	15
32	Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies?. Future Oncology, 2015, 11, 2645-2654.	2.4	44
33	Liver X Receptor ligand cytotoxicity in colon cancer cells and not in normal colon epithelial cells depends on LXRÎ ² subcellular localization. Oncotarget, 2015, 6, 26651-26662.	1.8	27
34	Liver X receptor \hat{l}^2 activation induces pyroptosis of human and murine colon cancer cells. Cell Death and Differentiation, 2014, 21, 1914-1924.	11.2	127
35	The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. Nature Immunology, 2014, 15, 758-766.	14.5	187
36	Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nature Medicine, 2013, 19, 57-64.	30.7	634

#	Article	IF	Citations
37	Knock-down of the oxysterol receptor LXR \hat{l} ± impairs cholesterol efflux in human primary macrophages: Lack of compensation by LXR \hat{l} 2 activation. Biochemical Pharmacology, 2013, 86, 122-129.	4.4	48
38	Dacarbazine-Mediated Upregulation of NKG2D Ligands on Tumor Cells Activates NK and CD8 T Cells and Restrains Melanoma Growth. Journal of Investigative Dermatology, 2013, 133, 499-508.	0.7	75
39	SOCS3 Transactivation by PPARγ Prevents IL-17–Driven Cancer Growth. Cancer Research, 2013, 73, 3578-3590.	0.9	51
40	STAT3 activation. Jak-stat, 2013, 2, e23010.	2.2	159
41	Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells. PLoS ONE, 2013, 8, e65181.	2.5	103
42	Production of Adenosine by Ectonucleotidases: A Key Factor in Tumor Immunoescape. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-9.	3.0	87
43	FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial. Annals of Oncology, 2012, 23, 2552-2561.	1.2	31
44	Immunomodulation and Anti-inflammatory Roles of Polyphenols as Anticancer Agents. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 852-873.	1.7	76
45	1080 Dacarbazine-mediated Upregulation of NKG2D Ligands on Tumor Cells Activates NK and CD8 T Cells and Prevents Melanoma Growth. European Journal of Cancer, 2012, 48, S260.	2.8	0
46	Stat3 and Gfi-1 Transcription Factors Control Th17 Cell Immunosuppressive Activity via the Regulation of Ectonucleotidase Expression. Immunity, 2012, 36, 362-373.	14.3	275
47	Identification of Biological Markers of Liver X Receptor (LXR) Activation at the Cell Surface of Human Monocytes. PLoS ONE, 2012, 7, e48738.	2.5	12
48	Tumor Exosome-Mediated MDSC Activation. American Journal of Pathology, 2011, 178, 1403-1405.	3.8	25
49	Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2011, 125, 65-72.	2.5	115
50	<i>In situ</i> immune response after neoadjuvant chemotherapy for breast cancer predicts survival. Journal of Pathology, 2011, 224, 389-400.	4.5	204
51	T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. British Journal of Cancer, 2011, 105, 366-371.	6.4	56
52	Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. Journal of Clinical Investigation, 2010, 120, 457-71.	8.2	761
53	5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity. Cancer Research, 2010, 70, 3052-3061.	0.9	1,098
54	Liver X Receptor–Mediated Induction of Cholesteryl Ester Transfer Protein Expression Is Selectively Impaired in Inflammatory Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1923-1929.	2.4	21

#	Article	IF	Citations
55	Induction of Transglutaminase 2 by a Liver X Receptor/Retinoic Acid Receptor α Pathway Increases the Clearance of Apoptotic Cells by Human Macrophages. Circulation Research, 2009, 105, 393-401.	4.5	96
56	$7\hat{l}^2$ -Hydroxycholesterol and 25-hydroxycholesterol-induced interleukin-8 secretion involves a calcium-dependent activation of c-fos via the ERK1/2 signaling pathway in THP-1 cells. Cell Biology and Toxicology, 2009, 25, 127-139.	5 . 3	48
57	Docosahexaenoic Acid Induces Increases in [Ca ²⁺] _i via Inositol 1,4,5-Triphosphate Production and Activates Protein Kinase Cl³ and -l´ via Phosphatidylserine Binding Site: Implication in Apoptosis in U937 Cells. Molecular Pharmacology, 2007, 72, 1545-1556.	2.3	47
58	Caspase-8 prevents sustained activation of NF- \hat{l}^{P} B in monocytes undergoing macrophagic differentiation. Blood, 2007, 109, 1442-1450.	1.4	125
59	Deglycosylated bleomycin induces apoptosis in lymphoma cell via c-jun NH2-terminal kinase but not reactive oxygen species. Biochemical Pharmacology, 2007, 74, 1445-1455.	4.4	9
60	Caspase-10 involvement in cytotoxic drug-induced apoptosis of tumor cells. Oncogene, 2006, 25, 7635-7645.	5. 9	28
61	Identification of Proteins Cleaved Downstream of Caspase Activation in Monocytes Undergoing Macrophage Differentiation*. Journal of Biological Chemistry, 2006, 281, 17779-17788.	3.4	53
62	Translocation of the inhibitor of apoptosis protein c-IAP1 from the nucleus to the Golgi in hematopoietic cells undergoing differentiation: a nuclear export signal-mediated event. Blood, 2004, 104, 2035-2043.	1.4	55
63	Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene, 2004, 23, 8979-8986.	5.9	181
64	Resveratrol-induced Apoptosis Is Associated with Fas Redistribution in the Rafts and the Formation of a Death-inducing Signaling Complex in Colon Cancer Cells. Journal of Biological Chemistry, 2003, 278, 41482-41490.	3.4	241
65	Bcl-2 Proteins: Targets and Tools for Chemosensitisation of Tumor Cells. Anti-Cancer Agents in Medicinal Chemistry, 2003, 3, 307-318.	7.0	31
66	CELL DEATH PATHWAYS AS TARGETS FOR ANTICANCER DRUGS. , 2002, , 55-76.		3
67	Specific involvement of caspases in the differentiation of monocytes into macrophages. Blood, 2002, 100, 4446-4453.	1.4	287
68	Intracellular redistribution of procaspases during TPA-induced differentiation of U937 human leukemic cells. Leukemia, 2002, 16, 1569-1570.	7.2	8
69	An atypical caspase-independent death pathway for an immunogenic cancer cell line. Oncogene, 2002, 21, 6091-6100.	5.9	13
70	Involvement of caspase-2 long isoform in Fas-mediated cell death of human leukemic cells. Blood, 2001, 97, 1835-1844.	1.4	57
71	Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. Blood, 2001, 97, 3931-3940.	1.4	79
72	Modulation of apoptosis by procaspase-2 short isoform: selective inhibition of chromatin condensation, apoptotic body formation and phosphatidylserine externalization. Oncogene, 2001, 20, 260-269.	5.9	36